Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 4/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.49 |
| ▸ | CDK7 | P50613 | 3/20 | 0.49 |
| ▸ | CCNH | P51946 | 3/20 | 0.49 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.49 |
| ▸ | CCNK | O75909 | 2/20 | 0.47 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 5/20 | 0.47 |
| ▸ | ITK | Q08881 | 3/20 | 0.47 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.44 |
| ▸ | BTK | Q06187 | 3/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30191034 | 0.88 | FGFR4 (0.49) | FGFR4CCNA2CDK2CDK7CCNH | |
| SCHEMBL24151293 | 0.88 | FGFR4 (0.49) | FGFR4CCNA2CDK2CDK7CCNH | |
| SCHEMBL30190403 | 0.87 | FGFR4 (0.46) | FGFR4CCNA2CDK2CDK7CCNH | |
| SCHEMBL24150994 | 0.87 | FGFR4 (0.46) | FGFR4CCNA2CDK2CDK7CCNH | |
| SCHEMBL24150847 | 0.85 | CDK7 (0.46) | FGFR4CCNA2CDK2CDK7CCNH | |
| SCHEMBL24150212 | 0.85 | FGFR4 (0.46) | FGFR4CCNA2CDK2CDK7CCNH | |
| SCHEMBL30190825 | 0.84 | JAK3 (0.57) | EGFRITKPLCG1BTK | |
| SCHEMBL24150531 | 0.84 | JAK3 (0.57) | EGFRITKPLCG1BTK | |
| SCHEMBL24150902 | 0.82 | FGFR4 (0.52) | FGFR4FGFR1 | |
| SCHEMBL30190902 | 0.82 | FGFR4 (0.52) | FGFR4FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2021262596-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | FGFR4 3079/4885CCNA2 295/4885CDK2 361/4885 |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | FGFR4 3079/4885CCNA2 295/4885CDK2 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.